ScoreWhy is Arbutus Biopharma Corp. ?
1
With a growth in Net Sales of 16943.39%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -34.44 MM
- NET SALES(HY) Higher at USD 180.18 MM
- ROCE(HY) Highest at 94.73%
2
With ROE of -29.24%, it has a attractive valuation with a 10.95 Price to Book Value
- Over the past year, while the stock has generated a return of 31.78%, its profits have risen by 64.8%
3
High Institutional Holdings at 73.56%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 5.02% over the previous quarter.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Arbutus Biopharma Corp. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Arbutus Biopharma Corp. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Arbutus Biopharma Corp.
31.78%
0.93
47.12%
S&P 500
25.22%
1.91
13.23%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
15.30%
EBIT Growth (5y)
8.84%
EBIT to Interest (avg)
-46.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.36
Sales to Capital Employed (avg)
0.12
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
73.56%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
10.95
EV to EBIT
-27.77
EV to EBITDA
-28.14
EV to Capital Employed
-68.87
EV to Sales
53.34
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-29.24%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend38What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -34.44 MM
NET SALES(HY)
Higher at USD 180.18 MM
ROCE(HY)
Highest at 94.73%
RAW MATERIAL COST(Y)
Fallen by -23.29% (YoY
OPERATING PROFIT(Q)
Highest at USD 169.13 MM
PRE-TAX PROFIT(Q)
Highest at USD 169.9 MM
NET PROFIT(Q)
Highest at USD 169.9 MM
EPS(Q)
Highest at USD 0.87
-5What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 186.7 MM
DEBT-EQUITY RATIO
(HY)
Highest at -35.1 %
DEBTORS TURNOVER RATIO(HY)
Lowest at 2.11 times
Here's what is working for Arbutus Biopharma Corp.
Net Sales
At USD 180.18 MM has Grown at 5,297.75%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 169.9 MM has Grown at 3,135.08%
over average net sales of the previous four periods of USD -5.6 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 169.9 MM has Grown at 3,135.08%
over average net sales of the previous four periods of USD -5.6 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD -34.44 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Higher at USD 180.18 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Operating Profit
Highest at USD 169.13 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 169.9 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 169.9 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.87
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -23.29% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Arbutus Biopharma Corp.
Cash and Eqv
Lowest at USD 186.7 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -35.1 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Debtors Turnover Ratio
Lowest at 2.11 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
